PomDoctor Ltd · Q1 2026 earnings

Briefing

Pomdoctor FY2025 revenue up 16.7% to RMB 399.9M as Internet hospital sales surge 69%

Pomdoctor Limited reported fiscal 2025 net revenues of RMB 399.9 million ($57.2 million), up 16.7% from RMB 342.6 million in fiscal 2024. Gross profit rose 9.6% to RMB 52.3 million with a 13.1% gross margin. Internet hospital revenue jumped 69.3% to RMB 150.7 million, driven by online pharmacy sales reaching RMB 149.2 million, while pharmaceutical supply chain revenue edged down 1.7% to RMB 249.2 million. The company posted a net loss of RMB 130.9 million, widened by IPO-related professional fees and investor relations costs, and basic loss per share was RMB 21.96. R&D spending increased 328.5% to RMB 12.9 million to support AI and healthcare technology initiatives following the October 2025 Nasdaq listing.

• FY2025 net revenue grew 16.7% to RMB 399.9M; gross profit up 9.6% to RMB 52.3M.
• Internet hospital revenue surged 69.3% to RMB 150.7M on online pharmacy expansion.
• Net loss widened to RMB 130.9M from RMB 37.4M, largely due to IPO-related expenses.
• Gross margin was 13.1%; Internet hospital margin 32.7% versus 42.7% prior year.
• Completed Nasdaq IPO in October 2025, raising $23.0M gross before fees.

Headline financials

Revenue & EPS history